FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:351-352 July 29, 1993 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In 1985, zidovudine was found to have in vitro activity against the human immunodeficiency virus (HIV). The first large clinical trial, initiated in February 1986 in patients with advanced HIV disease, was stopped by the safety monitoring board after seven months because there was a significant survival advantage for those who received zidovudine. The drug was approved by the Food and Drug Administration (FDA) in March 1987^1,2. Its efficacy has now been demonstrated for nearly every clinical and laboratory index that it makes sense to study. These include prolongation of survival, delay of the occurrence of an AIDS-defining diagnosis, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.